uniQure Revenue and Competitors
Estimated Revenue & Valuation
- uniQure's estimated annual revenue is currently $500.4M per year.
- uniQure's estimated revenue per employee is $584,579
- uniQure's current valuation is $934M. (January 2022)
Employee Data
- uniQure has 856 Employees.
- uniQure grew their employee count by 5% last year.
uniQure's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Executive Assistant to Chief Medical Officer and SVP, Regulatory Affairs | Reveal Email/Phone |
3 | Executive Assistant to Chief Medical Officer | Reveal Email/Phone |
4 | Chief People Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Biosafety officer | Reveal Email/Phone |
8 | Site Head and VP Operations | Reveal Email/Phone |
9 | VP, New Product Planning (Global and US Commercialization Strategy) | Reveal Email/Phone |
10 | VP, Clinical Development at uniQure, Inc. | Reveal Email/Phone |
uniQure Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -34% | N/A | N/A |
#2 | $12.7M | 82 | -7% | N/A | N/A |
#3 | $9.8M | 63 | -5% | N/A | N/A |
#4 | $6.4M | 41 | -5% | N/A | N/A |
#5 | $28.4M | 183 | -18% | N/A | N/A |
#6 | $43.7M | 282 | 9% | N/A | N/A |
#7 | $11.3M | 73 | 1% | N/A | N/A |
#8 | $18.1M | 117 | 19% | N/A | N/A |
#9 | $0.8M | 5 | -55% | N/A | N/A |
#10 | $10.2M | 66 | 2% | N/A | N/A |
What Is uniQure?
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
keywords:N/A
N/A
Total Funding
856
Number of Employees
$500.4M
Revenue (est)
5%
Employee Growth %
$934M
Valuation
N/A
Accelerator
uniQure News
On behalf of the Board of Directors of uniQure N.V. (the Company), I invite you to attend our 2022 Annual General Meeting of Shareholders...
uniQure N.V. (NASDAQ:QURE) is a great speculative biotech to look into. The reason why I state this is because its main clinical program,...
The multi-year clinical development was led by uniQure (NASDAQ:QURE) and sponsorship of the trials in the U.S. has transitioned to CSL Behring...
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $159.5M | 858 | 0% | N/A |
#2 | $175.4M | 864 | 3% | N/A |
#3 | $202.4M | 869 | 9% | N/A |
#4 | $300M | 875 | 17% | N/A |
#5 | $3.5M | 893 | 33% | N/A |